ClinicalTrials.gg
CompletedNCT04609566Updated Jul 6, 2026

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

A Phase 2 interventional study of brentuximab vedotin and pembrolizumab in Melanoma, Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Completed at 90 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing pembrolizumab in Melanoma — 20 open to participants now, 41 under way, 7 of them phase 3. pembrolizumab · Melanoma.

Enrollment
18th of 87
161 · median 53
Started
2021
with 8 others
Phase 2
49 of 87
12 open now
Registered
55th of 87
by date

Among the 87 studies testing pembrolizumab in Melanoma, this one is the 18th largest by enrollment, is one of 9 that started in 2021, is one of 49 in phase 2, and was the 55th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

20 of the 87 studies testing pembrolizumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing pembrolizumab in Melanoma, or all of them as a file.
02

Study summary

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic).

The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer.

This is a multi-cohort study.

03

Conditions studied

  • Melanoma
  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have

    • squamous or nonsquamous non-small cell lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) who either

      • a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti /PD-L1 or
      • b) are with progression on anti PD-1/PD therapy.
    • Relapsed/refractory metastatic cutaneous melanoma (regardless of mutation status) with progression on a PD-1 inhibitor
    • Metastatic head and neck squamous cell carcinoma (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1/PD-L1 inhibitor.
  • Cohorts 1-4 only: Melanoma participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g. nivolumab or pembrolizumab) or had their last dose of PD-1 CPI containing therapy as the last within 90 days prior to enrollment; PD-1 CPI therapy must be the immediate prior line of treatment.
  • Cohorts 1-4 only: Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other CPIs or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria.

    • Have received at least 2 doses of an approved PD-1 inhibitor.
    • Have demonstrated disease progression (PD) after a PD-1 inhibitor as defined by v1.1.

      • Progressive disease has been documented within 90 days from the last dose of PD-1 inhibitor.
      • Participants with melanoma will need confirmation of progression with a second assessment at least four weeks after the initial date of progressive disease
      • NSCLC participants on PD-1 inhibitor containing therapy for less than 90 days will need iRECIST confirmation of progression at least 4 weeks after the initial date of progressive disease
  • Tumor tissue sample obtained within 3 months prior to enrollment is required, and no systemic anticancer therapy given after the sample was obtained.
  • An (ECOG) Performance Status score of equal or less than 1

Exclusion criteria

Exclusion Criteria

  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Prior chemotherapy, any immunotherapy other than a inhibitor within 4 weeks of first study drug dose.
  • History of another within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Combination Therapy

    brentuximab vedotin + pembrolizumab

    Drug: brentuximab vedotin · Drug: pembrolizumab

Interventions

  • 1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks

    Also known as: ADCETRIS

  • 200 mg given intravenously every 3 weeks

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria

    Confirmed ORR per RECIST v1.1 is defined as the proportion of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Duration of response (DOR) based on investigator assessment using RECIST v1.1 criteria

    DOR per RECIST v1.1 is defined as the time from start of the first documentation of confirmed objective tumor response (CR or PR) per RECIST v1.1 to the first documentation of PD (per RECIST v1.1) or to death due to any cause, whichever comes first.

    Time frame: Up to approximately 3 years

  2. Progression-free survival (PFS) based on investigator assessment using RECIST v1.1 criteria

    PFS is defined as the time from start of study treatment to first documentation of objective tumor progression (PD per RECIST v1.1), or to death due to any cause, whichever comes first.

    Time frame: Up to approximately 3 years

  3. ORR per iRECIST by investigator assessment

    ORR per iRECIST is defined as the proportion of participants with confirmed CR or PR based on iRECIST guidelines

    Time frame: Up to approximately 2 years

  4. iDOR per iRECIST by investigator assessment

    DOR per iRECIST is defined as the time from first documentation of confirmed objective response (CR or PR) based on iRECIST guidelines by investigator assessment to the first documentation of confirmed objective tumor progression per iRECIST by investigator assessment, or to death due to any cause, whichever comes first.

    Time frame: Up to approximately 3 years

  5. iPFS per iRECIST by investigator assessment

    iPFS is defined as the time from start of study treatment to the first documentation of confirmed objective tumor progression per iRECIST by investigator assessment, treatment discontinuation following the unconfirmed progression or death due to any cause, whichever comes first.

    Time frame: Up to approximately 3 years

  6. Incidence of adverse events (AEs)

    National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Analyses of AEs will be summarized with descriptive statistics.

    Time frame: Up to approximately 2 years

07

Study locations

90 sites
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85711, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85745, United States
  • Highlands Oncology Group, PA
    Fayetteville, Arkansas 72703, United States
  • Highlands Oncology Group, PA
    Rogers, Arkansas 72758, United States
  • Highlands Oncology Group, PA
    Springdale, Arkansas 72762, United States
  • California Cancer Associates for Research and Excellence, Inc (cCARE)
    Encinitas, California 92024, United States
  • California Cancer Associates for Research and Excellence, Inc. cCARE
    Fresno, California 93720, United States
  • The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
    Los Angeles, California 90025, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)
    Los Angeles, California 90048, United States
  • California Cancer Associates for Research and Excellence Inc (cCARE)
    San Marcos, California 92069, United States
  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-Up Only)
    Santa Monica, California 90404, United States
  • Rocky Mountain Cancer Centers, LLP
    Aurora, Colorado 80012, United States
  • Clinical and Translational Research Center (CTRC)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital-Anschutz Cancer Pavilion (ACP)
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers, LLP
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers, LLP
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer Centers, LLP
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers, LLP
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers, LLP
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers, LLP
    Longmont, Colorado 80504, United States
  • Rocky Mountain Cancer Centers, LLP
    Pueblo, Colorado 81003, United States
  • Rocky Mountain Cancer Centers, LLP
    Thornton, Colorado 80260, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Norton Cancer Institute Downtown
    Louisville, Kentucky 40202, United States
  • Norton Hospital
    Louisville, Kentucky 40202, United States
  • Norton Audubon Hospital
    Louisville, Kentucky 40217, United States
  • Norton Cancer Institute, Audubon Hospital Campus
    Louisville, Kentucky 40217, United States
  • Norton Brownsboro Hospital
    Louisville, Kentucky 40241, United States
  • Norton Cancer Institute, Brownsboro Hospital Campus
    Louisville, Kentucky 40241, United States
  • Minnesota Oncology Hematology PA
    Burnsville, Minnesota 55337, United States
  • Minnesota Oncology Hematology PA
    Coon Rapids, Minnesota 55433, United States
  • Minnesota Oncology Hematology PA
    Edina, Minnesota 55435, United States
  • Minnesota Oncology Hematology PA
    Fridley, Minnesota 55432, United States
  • Minnesota Oncology Hematology PA
    Maple Grove, Minnesota 55369, United States
  • Minnesota Oncology Hematology PA
    Maplewood, Minnesota 55109, United States
  • Minnesota Oncology Hematology PA
    Minneapolis, Minnesota 55404, United States
  • Minnesota Oncology Hematology PA
    Plymouth, Minnesota 55441, United States
  • Minnesota Oncology Hematology PA
    Saint Paul, Minnesota 55102, United States
  • Minnesota Oncology Hematology PA
    Woodbury, Minnesota 55125, United States
  • Nebraska Medicine - Bellevue Medical Center
    Bellevue, Nebraska 68123, United States
  • Nebraska Medicine
    Omaha, Nebraska 68105, United States
  • Nebraska Medicine - Village Pointe
    Omaha, Nebraska 68118, United States
  • University Of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • New York Oncology Hematology, P.C.
    Clifton Park, New York 12065, United States
  • Oncology_Hematology Care Clinical Trials,LLC
    Cincinnati, Ohio 45211, United States
  • Oncology_Hematology Care Clinical Trials,LLC
    Cincinnati, Ohio 45236, United States
  • Oncology_Hematology Care Clinical Trials,LLC
    Cincinnati, Ohio 45242, United States
  • Oncology_Hematology Care Clinical Trials,LLC
    Cincinnati, Ohio 45245, United States
  • Oncology_Hematology Care Clinical Trials,LLC
    Fairfield, Ohio 45014, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • Oncology Associates of Oregon, P.C.
    Eugene, Oregon 97401, United States
  • Texas Oncology - Central South
    Austin, Texas 78705, United States
  • Texas Oncology - Central South (Balcones Dr)
    Austin, Texas 78731, United States
  • Texas Oncology - Central South (James Casey)
    Austin, Texas 78745, United States
  • Texas Oncology-DFW
    Dallas, Texas 75246, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • Texas Oncology - Fort Worth Cancer Center
    Fort Worth, Texas 76104, United States
  • Texas Oncology-DFW
    Fort Worth, Texas 76104, United States
  • Oncology Consultants, PA
    Houston, Texas 77024, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Blacksburg, Virginia 24060, United States
  • Virginia Oncology Associates
    Chesapeake, Virginia 23320, United States
  • Inova Schar Cancer Institue Infusion Pharmacy
    Fairfax, Virginia 22031, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Hampton, Virginia 23666, United States
  • Oncology & Hematology Associates of Southwest Virginia Inc.
    Low Moor, Virginia 24457, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Commonwealth University Massey Cancer Center
    Richmond, Virginia 23219, United States
  • VCU Health Stony Point
    Richmond, Virginia 23235, United States
  • Massey Cancer Center Clinical & Translational Research Lab
    Richmond, Virginia 23298, United States
  • Tissue and Data Acquisition and Analysis Core (TDAAC)
    Richmond, Virginia 23298, United States
  • VCU Health- Adult Outpatient Pavilion (AOP) Investigational Drug Services
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • VCU Health Community Memorial Hospital
    South Hill, Virginia 23970, United States
  • VCU Health Tappahannock Hospital
    Tappahannock, Virginia 22560, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • Virginia Oncology Associates
    Williamsburg, Virginia 23188, United States
  • Oncology & Hematology Associates of Southwest Virginia, INC.
    Wytheville, Virginia 24382, United States
  • Fred Hutchinson Cancer Care Center
    Seattle, Washington 98109, United States
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Feb 2026, 60 months.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 60 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2020
First posted
Oct 30, 2020
StartActual
Jan 26, 2021
Primary completionActual
Feb 3, 2026
CompletionActual
Feb 3, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04609566
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Jan 26, 2021
Primary completion
Feb 3, 2026
Completion
Feb 3, 2026
Last update
Jul 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Pembrolizumab

Start the discussion